Skip to main content

Neptune Wellness Solutions Inc. (NEPT-T) Quote

Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 6.25
Day High 6.67
Open:6.27
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Neptune Wellness Solutions Inc is a health and wellness products company. The company is engaged in extraction, purification, and formulation of value-added differentiated science-based products. The company is focusing on five main areas namely Cannabis, Ingredients, Turnkey Solutions, Pet Supplements, and Consumer Brand. Currently, the company develops turnkey nutrition product solutions available in various unique delivery forms, offers specialty ingredients such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and a variety of other marine and seed oils.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Researchers aim to Build Credibility for CBD Products Following Shift in Regulations
PR Newswire - Thu Jul 11, 8:00AM CDT
PR Newswire - CMTX
Thu Jul 11, 8:00AM CDT
The cost of medical expenses can pile up very quickly for some. According to a survey conducted by Eventbrite, an average American spends approximately USD 199 each month on self-medication. In total, a typical American can spend upwards of USD 143,280 in their lifetime to treat themselves. Self-medicating is considered purchasing an over-the-counter (OTC) drug to treat a simple condition like headaches or a common cold. However, often times, medical attention is required for more severe cases. Certain therapies and treatments can cost thousands of dollars, potentially even hundreds of thousands depending on the severity of the condition. For instance, treatment of epilepsy (VNS therapy) in the U.S. can cost as much as USD 20,000, which includes implants and a surgical procedure. However, the cost of the surgery can vary throughout parts of the U.S. and can increase over time, according to the Epilepsy Foundation of Greater Chicago. Due to the rising costs of medical treatments, researchers and medical institutions have sought out alternatives to offer consumers cheaper options. Notably, cannabis has become a popular alternative within the healthcare marketplace, as specifically, CBD or cannabidiol is being leveraged across global markets because of its therapeutic benefits. Researchers have discovered that CBD can effectively be used to treat a variety of medical conditions, including cancer, arthritis, multiple sclerosis, and even epilepsy. Remarkably, the U.S. Food and Drug Administration approved the first-ever cannabis-based drug in 2018, Epidiolex, which is used to treat Dravet syndrome and Lennox-Gastaut syndrome, a form of epilepsy common among children. However, the FDA explicitly stated that more positive and large-scale clinical trials are required before the agency can approve more cannabis-based treatments. And as a result, scientists and researchers are now undergoing vigorous trials to uncover the efficacy of CBD. According to data compiled by Acumen Research and Consulting, the global cannabidiol market is projected to reach a market value of USD 22 Billion by 2026. Additionally, the market is expected to grow at a CAGR of 33% over the forecast period from 2019 to 2026. Pressure BioSciences, Inc. (OTC: PBIO), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT), Sorrento Therapeutics, Inc. (NASDAQ: SRNE), iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN)
The Must-Know Cannabis Stocks Before Vapes Hit Canadian Shelves in December 2019
PR Newswire - Wed Jul 10, 7:50AM CDT
PR Newswire - CMTX
Wed Jul 10, 7:50AM CDT
Consumer buying habits are shifting, as the cannabis industry evolves. As that happens, investors are being offered incredible opportunities. For example, according to GMP Securities, "demand for extracted products is going to explode this fall with the arrival of vape pens and infused products," as quoted by Marijuana Business Daily, adding that vape pens could lead with 20% of the extracts sector. In addition, Aphria Inc. says, "The expected legalization of vapes and concentrates will mark a significant turning point in the Canadian market, providing more choice and new experiences, while opening the door to a range of new consumers," adding that vapes and concentrates will represent close to 30% of the entire Canadian adult-use market by 2021. Better, Canadian consumers will be able to buy edibles, concentrates, and vape pens in mid to late December 2019 after Health Canada released the final version of regulations. That's opening a wide range of opportunity for companies including Vapen MJ Ventures (CSE: VAPN), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), Aphria Inc. (NYSE:APHA) (TSX: APHA), and GW Pharmaceuticals PLC (NASDAQ: GWPH).
Neptune Appoints Michael Cammarata as Chief Executive Officer
PR Newswire - Mon Jul 8, 5:30AM CDT
PR Newswire - PRNW
Mon Jul 8, 5:30AM CDT
LAVAL, QC , July 8, 2019 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ: NEPT) (TSX: NEPT) announced today the appointment of Michael Cammarata , a successful entrepreneur and innovator in the wellness industry, as its Chief Executive Officer and Member of the Board of Directors effective today, July 8, 2019 . After over 4 years, Jim Hamilton has stepped down from his role as CEO and Director but will remain as an advisor to the Board.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 5.50 +17.27% increase
on 07/02/19
Period Open:5.75
Price movement based on the high, low and last over the given period.
6.67 -3.30% decrease
on 07/15/19
+0.70 (+12.17%) increase
since 06/14/19
3-Month 4.80 +34.37% increase
on 04/16/19
Period Open:4.85
Price movement based on the high, low and last over the given period.
6.96 -7.33% decrease
on 06/10/19
+1.60 (+32.99%) increase
since 04/15/19
52-Week 3.31 +94.86% increase
on 12/24/18
Period Open:4.30
Price movement based on the high, low and last over the given period.
6.96 -7.33% decrease
on 06/10/19
+2.15 (+50.00%) increase
since 07/13/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).